ALK and non-small cell lung carcinoma: Two drugs for non-small-cell lung carcinoma (NSCLC) were approved, namely dacomitinib (VizimproTM) for EGRF-mutated NSCLC and lorlatinib (LorbrenaTM) for ALK-positive metastatic NSCLC (Figure 16).